Iovance Biotherapeutics, Inc.(IOVA)Earnings, Financials & Key RatiosIovance Biotherapeutics, Inc. (IOVA) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's precarious liquidity position, evidenced by only $196.5 million in cash against consistent quarterly operating losses, warrants extreme caution regarding potential future dilution.
Iovance Biotherapeutics, Inc. (IOVA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Iovance Biotherapeutics, Inc. (IOVA) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.19vs $0.19+0.0% | $71Mvs $78M-8.2% |
| Q1 2026 | Feb 24, 2026 | $0.18vs $0.22+18.2% | $87Mvs $81M+7.4% |
| Q4 2025 | Nov 6, 2025 | $0.25vs $0.29+13.8% | $67Mvs $82M-17.9% |
| Q3 2025 | Aug 7, 2025 | $0.33vs $0.29-13.8% | $60Mvs $78M-23.5% |
Recent stock market news and headlines for Iovance Biotherapeutics, Inc. (IOVA)
Heartflow leverages AI-enabled software to dominate the non-invasive coronary diagnostic market, backed by a stable base of over 1,450 accounts. Iovance Biotherapeutics is pioneering personalized TIL therapies for cancer, backed by centralized manufacturing and significant revenue growth from its lead products.
Amgen provides a stable, diversified revenue base of nearly $36.7 billion with significant net income. Iovance Biotherapeutics offers high growth potential through its innovative cell therapies for advanced cancers.
SAN CARLOS, Calif., June 19, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on June 18, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 140,860 shares of Iovance's common stock to twenty-seven new, non-executive employees.
IOVA guides for $350M–$370M 2026 revenue (36% YoY growth), with Q2'26 expected to be a record Amtagvi quarter. Expansion into new indications (NSCLC, endometrial, sarcoma) and global markets underpins the pipeline-in-a-drug thesis. A more receptive FDA increases the likelihood of accelerated approvals based on single-arm data, streamlining IOVA's development path.
Key metrics vs top competitors for Iovance Biotherapeutics, Inc. (IOVA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.35 | $1.56B | -3.99 | 60.6% | -148.38% | -55.5% | — | |
| $1.35 | $171.71M | -1.21 | 14.85% | -173.02% | — | — | |
| $3.02 | $352.01M | -2.63 | -51.24% | -2056.79% | -58.89% | — | |
| $60.77 | $5.86B | -9.39 | -89.97% | -13856.54% | -30.88% | — | |
| $17.43 | $1.96B | -4.57 | 16.92% | -597.04% | -57.27% | — | |
| $37.92 | $3.9B | -46.81 | 120.01% | -49.17% | -5.89% | — |
Iovance Biotherapeutics, Inc. (IOVA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Iovance Biotherapeutics, Inc. (IOVA) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 7, 2026·SEC
Mar 20, 2026·SEC
Feb 24, 2026·SEC
Get notified when IOVA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Iovance Biotherapeutics, Inc. (IOVA) stock FAQ — growth, dividends, profitability & financials explained
Iovance Biotherapeutics, Inc. (IOVA) reported $285.6M in revenue for fiscal year 2025.
Iovance Biotherapeutics, Inc. (IOVA) grew revenue by 60.6% over the past year. This is strong growth.
Iovance Biotherapeutics, Inc. (IOVA) reported a net loss of $353.9M for fiscal year 2025.
Iovance Biotherapeutics, Inc. (IOVA) has a return on equity (ROE) of -55.5%. Negative ROE indicates the company is unprofitable.
Iovance Biotherapeutics, Inc. (IOVA) had negative free cash flow of $305.0M in fiscal year 2025, likely due to heavy capital investments.
